CL2017003500A1 - Síntesis total de shishijimicina a y sus análogos - Google Patents

Síntesis total de shishijimicina a y sus análogos

Info

Publication number
CL2017003500A1
CL2017003500A1 CL2017003500A CL2017003500A CL2017003500A1 CL 2017003500 A1 CL2017003500 A1 CL 2017003500A1 CL 2017003500 A CL2017003500 A CL 2017003500A CL 2017003500 A CL2017003500 A CL 2017003500A CL 2017003500 A1 CL2017003500 A1 CL 2017003500A1
Authority
CL
Chile
Prior art keywords
shishijimycin
analogues
compounds
disclosure
total synthesis
Prior art date
Application number
CL2017003500A
Other languages
English (en)
Inventor
Kyriacos Nicolaou
Ruotan Li
Zhaoyong Lu
Te-Ik Sohn
James Woods
Emmanouil N Pitsinos
Original Assignee
Univ Rice William M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rice William M filed Critical Univ Rice William M
Publication of CL2017003500A1 publication Critical patent/CL2017003500A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>EN UN ASPECTO, LA PRESENTE DIVULGACIÓN PROVEE ANÁLOGOS DE SHISHIJIMICINA DONDE LAS VARIABLES TIENEN LOS VALORES QUE SE DEFINEN EN LA MEMORIA DESCRIPTIVA. EN OTRO ASPECTO, LA PRESENTE DIVULGACIÓN TAMBIÉN PROVEE MÉTODOS DE PREPARACIÓN DE DICHOS COMPUESTOS. EN OTRO ASPECTO, LA PRESENTE DIVULGACIÓN TAMBIÉN PROVEE COMPOSICIONES FARMACÉUTICAS Y MÉTODOS DE USO DE LOS COMPUESTOS. ADICIONALMENTE, SE PROVEEN CONJUGADOS ANTICUERPO-FÁRMACO QUE CONTIENEN LOS COMPUESTOS.</p>
CL2017003500A 2015-06-29 2017-12-29 Síntesis total de shishijimicina a y sus análogos CL2017003500A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562186191P 2015-06-29 2015-06-29

Publications (1)

Publication Number Publication Date
CL2017003500A1 true CL2017003500A1 (es) 2018-04-27

Family

ID=57609044

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003500A CL2017003500A1 (es) 2015-06-29 2017-12-29 Síntesis total de shishijimicina a y sus análogos

Country Status (19)

Country Link
US (1) US10590158B2 (es)
EP (1) EP3313389A1 (es)
JP (1) JP2018525346A (es)
KR (1) KR20180053294A (es)
CN (1) CN108348489A (es)
AR (1) AR105193A1 (es)
AU (1) AU2016286071A1 (es)
BR (1) BR112017028557A2 (es)
CA (1) CA2990206A1 (es)
CL (1) CL2017003500A1 (es)
HK (1) HK1254923A1 (es)
IL (1) IL256345A (es)
MA (1) MA42273A (es)
MX (1) MX2017016885A (es)
PE (1) PE20180658A1 (es)
PH (1) PH12018500014A1 (es)
RU (1) RU2018102808A (es)
TW (1) TW201713634A (es)
WO (1) WO2017004172A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110357785B (zh) * 2019-07-26 2020-03-24 东莞市领创环保材料科技有限公司 一种氰酸酯树脂增塑剂的制备方法
CN115197188B (zh) * 2021-04-12 2023-12-26 南开大学 一类具有五环骨架的倍半萜氢醌化合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5261586A (en) * 1992-03-26 1993-11-16 Chen Jen Fu Yarn feeding device with a guiding flange
US5550246A (en) * 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
JP2003238584A (ja) * 2002-02-08 2003-08-27 Yamanouchi Pharmaceut Co Ltd 新規エンジイン化合物
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
AU2012395148B2 (en) * 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules

Also Published As

Publication number Publication date
CN108348489A (zh) 2018-07-31
RU2018102808A (ru) 2019-07-30
IL256345A (en) 2018-02-28
PH12018500014A1 (en) 2018-07-09
KR20180053294A (ko) 2018-05-21
WO2017004172A1 (en) 2017-01-05
MX2017016885A (es) 2018-09-06
AU2016286071A1 (en) 2018-02-01
BR112017028557A2 (pt) 2018-09-04
MA42273A (fr) 2018-05-02
EP3313389A1 (en) 2018-05-02
WO2017004172A8 (en) 2018-01-11
TW201713634A (zh) 2017-04-16
PE20180658A1 (es) 2018-04-17
US10590158B2 (en) 2020-03-17
CA2990206A1 (en) 2017-01-05
HK1254923A1 (zh) 2019-08-02
AU2016286071A8 (en) 2019-08-08
AR105193A1 (es) 2017-09-13
RU2018102808A3 (es) 2020-04-30
US20180327439A1 (en) 2018-11-15
JP2018525346A (ja) 2018-09-06

Similar Documents

Publication Publication Date Title
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
CR20160419A (es) Nuevos compuestos biciclicos
CO2018007443A2 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2017003258A1 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CL2018003474A1 (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CR20180320A (es) Compuestos inhibidores de la quinasa de union a tank
UY37410A (es) Antagonistas de trpv4
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
CO7121325A2 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
CL2016003048A1 (es) Analogos de panonina minimas sintesis y uso de los mismos.
ECSP17057131A (es) Desacetoxitubulisina h y análogos de esta
CO2018003466A2 (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY37669A (es) Conjugados de fármaco-anticuerpo (adc) anti-prlr y usos de los mismos
CY1124057T1 (el) Διαμορφωτες υποδοχεων χ ηπατος (lxr)
SV2016005331A (es) Derivados de naftiridinadiona
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
CL2017003500A1 (es) Síntesis total de shishijimicina a y sus análogos
AR100204A1 (es) Compuesto de 1,1-adipoilbis(pirrolidina-2-carboxilato), composición farmacéutica que lo comprende y conjunto de partes que los incluye
JP2019529462A5 (ja) Ｔｎｆｒｓｆ １４抑制物質を含む皮膚美白用組成物
CO2017004382A2 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral
ECSP17046657A (es) Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina
GT201200066A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen